In a biotech landscape dominated by billion-dollar IPOs and sprawling R&D facilities, AsisChem operates with radical efficiency: 7 employees, $1.1M in revenue, and a laser focus on custom chemistry that cuts through the noise.

"This isn't a company building a product—it's a precision instrument for molecular problem-solving."

The tech stack reveals a company that's moved beyond MVP but refuses enterprise bloat. Tailwind CSS, Bootstrap, and jQuery suggest a pragmatic approach—stable, battle-tested tools that let a small team focus on chemistry, not frontend innovation. The absence of heavy frameworks like React or Vue is telling: they're not building a platform, they're building a laboratory.

• Hyper-specialized chemistry: The 'ASIS-06XX' series suggests proprietary synthetic pathways
• Global execution: US-Russia team structure enables round-the-clock R&D
• Direct-to-researcher model: 50% direct traffic indicates scientists bookmark and return
• No social footprint: They don't market—they discover